002932，重大资产重组！

Core Viewpoint - Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd., marking a significant strategic move towards enhancing its capabilities in emergency medical services [1][3]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will be executed in cash without involving share issuance [3]. - The acquisition does not involve related party transactions and will not lead to changes in the controlling shareholder or actual controller of Mingde Biological [3]. - The target company specializes in emergency rescue products, particularly first aid kits, and has a strong presence in both industrial and consumer markets [3][4]. Group 2: Strategic Importance - This acquisition aligns with Mingde Biological's strategic focus on the critical care sector, allowing for an integrated approach to emergency diagnosis and treatment [4]. - The complementary nature of the product lines and customer bases between Mingde Biological and the target company is expected to enhance market positioning and competitiveness in the emergency medical field [4]. Group 3: Market Information - Mingde Biological's latest stock price is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].